Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans



Status:Recruiting
Healthy:No
Age Range:21 - 35
Updated:9/15/2018
Start Date:July 1, 2012
End Date:June 30, 2019
Contact:Christina L Luddy, BS
Email:christina.luddy@va.gov
Phone:(203) 932-5711

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is
looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's
effects on driving an automobile.

Alcohol is abused commonly, but there is no antidote for alcohol intoxication the way
naltrexone or naloxone is an antidote for opioids. A medication that has the potential to
block alcohol actions in the Central Nervous System could act as a unique medication in the
treatment of alcohol intoxication and alcoholism. This project is evaluating the
benzodiazepine partial inverse agonist, iomazenil, as an agent that could reverse alcohol's
effects on subjective intoxication, alcohol's effects on driving using a driving simulator
and on measures of electrophysiology in the laboratory in healthy subjects.

Inclusion Criteria:

- Males and females

- 21-35 years old

- Medically healthy

Exclusion Criteria:

- Under the age of 21 or greater than the age 35

- Positive pregnancy test

- History of seizures
We found this trial at
2
sites
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut 06516
Principal Investigator: Deepak D'Souza, MD MBBS
Phone: 203-932-5711
?
mi
from
West Haven, CT
Click here to add this to my saved trials
CERC (VISN1, West Haven, CT)
West Haven, Connecticut 06516
Phone: 203-932-4523
?
mi
from
West Haven, CT
Click here to add this to my saved trials